Status:
COMPLETED
High and Low Dose Carbidopa Treatment of Parkinson's Disease
Lead Sponsor:
Oregon Health and Science University
Conditions:
Parkinson's Disease
Eligibility:
All Genders
35-85 years
Phase:
PHASE2
Brief Summary
Hypothesis: We hypothesize that carbidopa in daily doses of 450mg will enter the central nervous system and partially inhibit AAAD, thereby reducing the decarboxylation of exogenous levodopa to dopami...
Detailed Description
A. Specific Aims: Parkinson's disease is a common neurodegenerative disorder characterized by the progressive motor symptoms of tremor, rigidity, and bradykinesia. The prevalence is estimated at 102-...
Eligibility Criteria
Inclusion
- Idiopathic Parkinson's disease
- Treatment with carbidopa/levodopa
- Motor fluctuations
Exclusion
- Dementia
- Hallucinations
- Age greater than 85
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT01399905
Start Date
March 1 2009
End Date
May 1 2011
Last Update
January 9 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239